Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cineole→

Cineole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
470-82-6
Molecular formula
C10H18O
Molecular weight
154.25 g/mol
Drug class
1,8-Cineole (eucalyptol)monoterpene oxide with mucolytic and anti-inflammatory properties
Mechanism of action
Modulates airway mucus secretion and may reduce inflammatory mediator production in respiratory mucosa. The relative contribution of secretolytic, mucolytic and anti-inflammatory actions depends on dose and formulation.
Indications / reported uses
  • Symptomatic relief of cough and mucus-related symptoms in selected respiratory conditions with authorised cineole products; this is the same active substance as eucalyptol and should not be assigned a separate salt- or name-based profile

Sources: NLM MeSH — 1,8-Cineole · PubMed — 1,8-Cineole respiratory clinical studies · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cineole Environmental Risk Assessment (ERA) (the Cineole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.